Verification study on the application value of ProMisE molecular typing in the prognosis evaluation of endometrial cancer
10.3969/j.issn.1671-8348.2025.08.020
- VernacularTitle:ProMisE分子分型在子宫内膜癌预后评估的应用价值验证研究
- Author:
Yuanyuan YONG
1
;
Tiaotiao YONG
;
Lixian WU
Author Information
1. 宁夏医科大学总医院妇科,银川 750004
- Keywords:
endometrial cancer;
ProMisE molecular classification;
prognosis evaluation;
application;
val-ue
- From:
Chongqing Medicine
2025;54(8):1877-1882
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the application value of the prospective molecular classification tool(ProMisE)molecular typing for endometrial cancer in the prognosis assessment.Methods A retrospective a-nalysis was conducted on the clinical data of 150 patients with endometrial cancer admitted to the General Hospital of Ningxia Medical University.The patients were divided into 4 groups according to ProMisE molec-ular typing:DNA polymerase ε(POLE)mutant type,mismatch repair protein(MMR-d)type,p53 wild type(p53wt type)and p53 mutant type(p53abn type)were compared.The clinicopathological characteristics,treatment regimens and prognosis of patients in each group were compared.Results Endometrial cancer pa-tients with different ProMisE molecular subtypes showed differences in age,tumor histological type,depth of myometrial invasion,lymph node metastasis,etc.,and the differences were statistically significant(P<0.05).Patients with POLE mutations are younger,have a better degree of tumor differentiation,and have the best prognosis.Patients with p53abn type have a relatively advanced tumor stage and the poorest prognosis.The prognosis of patients with MMR-d type and p53wt type lies between the two.Conclusion ProMisE mo-lecular typing can provide an important basis for the prognosis assessment of patients with endometrial cancer and is helpful for formulating individualized and precise treatment plans.
